Thrombin-targeted liposomes establish a sustained localized anticlotting barrier against acute thrombosis.

No abstract is available for this paper.

• Publication year

  2013

• Venue

  Molecular Pharmaceutics

• Publication date

  2013-10-10

• Fields of study

  Medicine, Chemistry

• Identifiers
  DOI 10.1021/mp400210qPMID 24063304PMCID PMC3946534
• External record

  Open on Semantic Scholar

• Source metadata

  Semantic Scholar, PubMed

• No claims are published for this paper.

• No concepts are published for this paper.

• Mechanisms of platelet activation by thrombin: a short history.

  2012cited by this paper
• Amine-modified graphene: thrombo-protective safer alternative to graphene oxide for biomedical applications.

  2012cited by this paper
• Thrombin‐inhibiting perfluorocarbon nanoparticles provide a novel strategy for the treatment and magnetic resonance imaging of acute thrombosis

  2011cited by this paper
• New therapeutic approaches to combat arterial thrombosis: better drugs for old targets, novel targets, and future prospects.

  2011cited by this paper
• Exosomes released by melanoma cells prepare sentinel lymph nodes for tumor metastasis.

  2011cited by this paper
• Thrombin induces platelet activation in the absence of functional protease activated receptors 1 and 4 and glycoprotein Ib-IX-V.

  2010cited by this paper
• Recent developments in liposomes, microparticles and nanoparticles for protein and peptide drug delivery.

  2010cited by this paper
• New antiplatelet drugs: beyond aspirin and clopidogrel

  2009cited by this paper
• Targeting atherosclerosis by using modular, multifunctional micelles

  2009cited by this paper
• New antiplatelet agents: why they are needed.

  2009cited by this paper
• New Antithrombotic Drugs

  2009cited by this paper
• Characterization of antiplatelet properties of silver nanoparticles.

  2009cited by this paper
• Anticoagulants in coronary artery disease.

  2008cited by this paper
• Triggers, targets and treatments for thrombosis

  2008cited by this paper
• The top 4 advances in antithrombotic care in the last year.

  2008cited by this paper
• New-concept chemotherapy by nanoparticles of biodegradable polymers: where are we now?

  2006cited by this paper
• Stealth liposomes: review of the basic science, rationale, and clinical applications, existing and potential

  2006cited by this paper
• Platelet aggregation testing in platelet-rich plasma: description of procedures with the aim to develop standards in the field.

  2005cited by this paper
• Platelet Aggregation Testing in Platelet-Rich Plasma

  2005cited by this paper
• Recent advances with liposomes as pharmaceutical carriers

  2005cited by this paper
• Platelet aggregation: turbidimetric measurements.

  2004cited by this paper
• Antithrombotic activity of dermatan sulfate in heparin cofactor II-deficient mice.

  2004cited by this paper
• Thrombin binding to GPIbα induces platelet aggregation and fibrin clot retraction supported by resting αIIbβ3 interaction with polymerized fibrin

  2003cited by this paper
• Thrombin binding to GPIbalpha induces platelet aggregation and fibrin clot retraction supported by resting alphaIIbbeta3 interaction with polymerized fibrin.

  2003cited by this paper
• Thrombin signalling and protease-activated receptors

  2000cited by this paper
• PAR3 is a cofactor for PAR4 activation by thrombin

  2000cited by this paper
• [New antithrombotic drugs].

  1999cited by this paper
• Cloning and characterization of human protease-activated receptor 4.

  1998cited by this paper
• A dual thrombin receptor system for platelet activation

  1998cited by this paper
• Preparation and characterization of liposomes as therapeutic delivery systems: a review.

  1995cited by this paper
• Direct thrombin inhibitors in cardiovascular medicine.

  1994cited by this paper
• Pharmacology of Synthetic Thrombin Inhibitors of the Tripeptide Type

  1992cited by this paper
• Clot-bound thrombin is protected from inhibition by heparin-antithrombin III but is susceptible to inactivation by antithrombin III-independent inhibitors.

  1990cited by this paper
• Fibrin monomer protects thrombin from inactivation by heparin-antithrombin III: implications for heparin efficacy.

  1989cited by this paper
• Kinetics of the inhibition of thrombin by hirudin.

  1986cited by this paper
• Colorimetric determination of phospholipids with ammonium ferrothiocyanate.

  1980cited by this paper
• Preparation of liposomes of defined size distribution by extrusion through polycarbonate membranes.

  1979cited by this paper
• The identification of platelets and platelet antigens in histological sections.

  1965cited by this paper

• Cellular and molecular mechanisms of thrombosis and thrombus-targeted thrombolytic strategies

  2025cites this paper
• Exploring peptide dendrimers for intestinal lymphatic targeting: formulation and evaluation of peptide dendrimer conjugated liposomes for enhancing the oral bioavailability of Asenapine maleate

  2024cites this paper
• Overview of Venous Thromboembolism and Emerging Therapeutic Technologies Based on Nanocarriers-Mediated Drug Delivery Systems

  2024cites this paper
• A Complete Sojourn of Gene Therapy Along with its Targeting Approaches for the Treatment of the Major Depressive Disorder.

  2023cites this paper
• Simultaneous Inhibition of Thrombosis and Inflammation Is Beneficial in Treating Acute Myocardial Infarction

  2023cites this paper
• Surface Modification of Lipid-Based Nanoparticles.

  2022cites this paper
• GPIIb/IIIa Receptor Targeted Rutin Loaded Liposomes for Site-Specific Antithrombotic Effect.

  2022cites this paper
• Immunoliposomes: A Targeted Drug Delivery System for Cancer Therapeutics and Vaccination.

  2022cites this paper
• Thrombolytic Agents: Nanocarriers in Targeted Release

  2021cites this paper
• Surface-engineered nanoliposomes with lipidated and non-lipidated peptide-dendrimeric scaffold for efficient transdermal delivery of a therapeutic agent: Development, characterization, toxicological and preclinical performance analyses.

  2020cites this paper
• COVID-19: Nanomedicine Uncovers Blood-Clot Mystery

  2020cites this paper
• Liposomal doxorubicin as targeted delivery platform: Current trends in surface functionalization.

  2020cites this paper
• Relevant Physicochemical Methods to Functionalize, Purify, and Characterize Surface-Decorated Lipid-Based Nanocarriers.

  2020cites this paper
• The physiological and pathological roles and applications of sialyl Lewis x, a common carbohydrate ligand of the three selectins

  2020cites this paper
• Nanoparticles for hematologic diseases detection and treatment

  2019cites this paper
• The use of nanotechnology in cardiovascular disease

  2018cites this paper
• Thrombin-activatable fluorescent peptide incorporated gold nanoparticles for dual optical/computed tomography thrombus imaging.

  2018cites this paper
• Liposomal discovery of diacylglycerol (DAG)-binding proteins and the use of signaling lipids to improve nanodrug delivery

  2018cites this paper
• Recent strategies to design vascular theranostic nanoparticles

  2017cites this paper
• Targeting and Triggered Release Using Lipid-Based Supramolecular Assemblies as Medicinal Nanocarriers

  2017cites this paper
• Optimizing the Performance of Supported Lipid Bilayers as Cell Culture Platforms Based on Extracellular Matrix Functionalization

  2017cites this paper
• DHDMIQK(KAP): a novel nano-delivery system of dihydroxyl-tetrahydro-isoquinoline-3-carboxylic acid and KPAK towards the thrombus.

  2016cites this paper
• The melding of nanomedicine in thrombosis imaging and treatment: a review

  2016cites this paper
• Thrombin‐Inhibiting Anticoagulant Liposomes: Development and Characterization

  2016cites this paper
• Liposomes as Drug Delivery Vehicles

  2016cites this paper
• Antithrombin nanoparticles inhibit stent thrombosis in ex vivo static and flow models.

  2016cites this paper
• Multifunctional Thrombin‐Activatable Polymer Capsules for Specific Targeting to Activated Platelets

  2015cites this paper
• Molecular imaging of atherosclerosis with nanoparticle-based fluorinated MRI contrast agents.

  2015cites this paper
• Modifications of natural peptides for nanoparticle and drug design.

  2015cites this paper
• Thrombosis: Novel nanomedical concepts of diagnosis and treatment.

  2015cites this paper
• Quantifying progression and regression of thrombotic risk in experimental atherosclerosis

  2015cites this paper
• Antithrombin nanoparticles improve kidney reperfusion and protect kidney function after ischemia-reperfusion injury.

  2015cites this paper
• TPA Immobilization on Iron Oxide Nanocubes and Localized Magnetic Hyperthermia Accelerate Blood Clot Lysis

  2015cites this paper
• Anti-thrombin nanoparticles improve kidney reperfusion and protect kidney function after

  2015cites this paper
• Ligation Strategies for Targeting Liposomal Nanocarriers

  2014influential citation
• Nanoparticle Incorporation of Melittin Reduces Sperm and Vaginal Epithelium Cytotoxicity

  2014cites this paper
• Nanoparticle systems that exploit host biology for diagnosis and treatment of disease

  2014cites this paper
• Cardiovascular therapy through nanotechnology – how far are we still from bedside?

  2014cites this paper
• Non-Enzymatic Remodeling of Fibrin Biopolymers via Photothermally Triggered Radical-Generating Nanoparticles

  2014cites this paper